top of page

Search Results

Results found for "AntlerA Therapeutics"

Posts (291)

  • Why Intracellular Drugs May Hold the Key to GPCR Therapeutics

    diffusion, offset kinetics, and rebinding ✅ Real-world examples of how residence time—not potency—predicts therapeutic The slow-offset compound stays on target longer, maintains therapeutic effect as concentrations drop, DrugResidenceTime #AllostericModulation #CytosolicKinetics #PK #PD #CellPermeabilityAssays #PAMPA #Caco2 #TherapeuticKinetics

  • Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes

    adipose tissue size more effectively than exendin, suggesting that biased agonism can lead to distinct therapeutic In conclusion, biased agonism at the GLP-1R represents a promising strategy for optimizing therapeutic continues to grow, it is likely to play an increasingly important role in the design of next-generation therapeutics Christopoulos, Signalling bias in new drug discovery: detection, quantification and therapeutic impact Drucker, D.J., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.  

  • Tectonic Therapeutic Strengthens Leadership Team

    July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON--Tectonic Therapeutic, Inc. a pre-clinical

View All

Other Pages (92)

  • Dr. Stephane Angers | Dr. GPCR Ecosystem

    He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Molecular Neurology and also Vice-Chair of the Department of Biomedical Sciences at the University of Antwerp Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Molecular Neurology and also Vice-Chair of the Department of Biomedical Sciences at the University of Antwerp Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

View All

Events (2)

View All
bottom of page